On Tuesday, CytomX Therapeutics Inc (NASDAQ: CTMX) was -5.17% drop from the session before settling in for the closing price of $1.16. A 52-week range for CTMX has been $1.04 – $5.85.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Over the past five-year period, the growth rate of yearbook sales for the company of the Healthcare sector was 28.25%. When this article was written, the company’s average yearly earnings per share was at -3053.00%. With a float of $76.79 million, this company’s outstanding shares have now reached $78.12 million.
Considering the fact that the conglomerate employs 122 people, you should pay attention to its efficiency factor. In terms of profitability, gross margin is 97.63%, operating margin of 4.79%, and the pretax margin is 12.61%.
CytomX Therapeutics Inc (CTMX) Insider Activity
Also, it is sometimes useful to examine the sentiment of large-scale investors toward CytomX Therapeutics Inc stocks. The insider ownership of CytomX Therapeutics Inc is 1.69%, while institutional ownership is 72.33%. The most recent insider transaction that took place on Aug 20 ’24, was worth 5,139. In this transaction Chief Business Officer of this company sold 4,181 shares at a rate of $1.23, taking the stock ownership to the 119,056 shares. Before that another transaction happened on Aug 20 ’24, when Company’s SVP, Chief Scientific Officer sold 4,181 for $1.23, making the entire transaction worth $5,139. This insider now owns 175,648 shares in total.
CytomX Therapeutics Inc (CTMX) Earnings and Forecasts
Going through the last 3-months fiscal report unveiled on the 6/30/2024, it has been observed that the corporation posted 0.04 earnings per share (EPS) during the time that was better than consensus figure (set at -0.19) by 0.23. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.2 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -3053.00% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -0.90% during the next five years compared to 67.21% growth over the previous five years of trading.
CytomX Therapeutics Inc (NASDAQ: CTMX) Trading Performance Indicators
You can see what CytomX Therapeutics Inc (CTMX) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 1.00. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 0.72.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 0.14, a number that is poised to hit -0.17 in the next quarter and is forecasted to reach -0.61 in one year’s time.
Technical Analysis of CytomX Therapeutics Inc (CTMX)
Compared to the last year’s volume of 2.65 million, its volume of 0.65 million showed lagged in the last five days. As of the previous 9 days, the stock’s Stochastic %D was 60.58%. Additionally, its Average True Range was 0.06.
During the past 100 days, CytomX Therapeutics Inc’s (CTMX) raw stochastic average was set at 3.27%, which indicates a significant decrease from 21.74% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 48.24% in the past 14 days, which was lower than the 56.67% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.1836, while its 200-day Moving Average is $1.6560. Nevertheless, the first resistance level for the watch stands at $1.1483 in the near term. At $1.1967, the stock is likely to face the second major resistance level. The third major resistance level sits at $1.2333. If the price goes on to break the first support level at $1.0633, it is likely to go to the next support level at $1.0267. Should the price break the second support level, the third support level stands at $0.9783.
CytomX Therapeutics Inc (NASDAQ: CTMX) Key Stats
There are 77,919K outstanding shares of the company, which has a market capitalization of 85.93 million. As of now, sales total 101,210 K while income totals -570 K. Its latest quarter income was 25,120 K while its last quarter net income were -6,530 K.
